Skip to main content

Day: August 25, 2022

Immuneering Announces Participation in September Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in two September investor conferences to share commentary around the Company’s pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer. Immuneering will participate in the following conferences: Wells Fargo 2022 Healthcare Conference, Boston, MAFormat: One-on-one meetingsDate: September 8, 2022 Morgan Stanley 20th Annual Global Healthcare Conference, New York, NYFormat: Fireside ChatDate: September...

Continue reading

Share forfeiture and cancellation

Downing ONE VCT plc LEI: 213800R88MRC4Y3OIW86Share forfeiture and cancellation25 August 2022 Downing ONE VCT plc announces that 7,907 Ordinary Shares of 0.1p each that were allotted on 5 April 2022 have now been forfeited and cancelled following the failure by an investor to pay the sum due on those shares issued under the Offer for  Subscription that launched on 26 November 2021 and closed on 29 April 2022. The forfeiture and cancellation of the shares has taken place in accordance with the process set out in the Company’s Articles of Association.

Continue reading

Glatfelter Announces Chief Executive Officer Transition

Non-Executive Chairman Role Established to Coincide with Change in Company Leadership CHARLOTTE, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT), a leading global supplier of engineered materials, today announced that Mr. Thomas Fahnemann has been appointed to the role of President and Chief Executive Officer, effective immediately. He replaces the Company’s current Chairman and Chief Executive Officer, Mr. Dante C. Parrini, who will be leaving the Company following a 25-year career. In addition, the Board has appointed Mr. Kevin M. Fogarty, currently an independent Glatfelter Board Director and Chairman of the Nominating and Corporate Governance Committee, to the role of Non-Executive Chairman. The Company noted that these changes are not related to Glatfelter’s operations, financial reporting or controls,...

Continue reading

Burlington Stores, Inc. Reports Second Quarter 2022 Earnings

All Second Quarter 2022 comparisons are made versus the Second Quarter 2021On a GAAP basis, total sales decreased 10% on top of a 34% increase in Q2 2021 Net income was $12 million, and diluted EPS was $0.18 Comparable store sales decreased 17%  on top of 19% growth in Q2 2021 On a non-GAAP basis, Adjusted EBIT was $43 million On a non-GAAP basis, Adjusted EPS was $0.35 versus guidance of $0.18 to $0.31BURLINGTON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) — Burlington Stores, Inc. (NYSE: BURL), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices, today announced its results for the second quarter ended July 30, 2022. Michael O’Sullivan, CEO, stated, “Our 17% comp sales decline for the quarter came in below our guidance of down 15%...

Continue reading

Titan Machinery Inc. Announces Results for Fiscal Second Quarter Ended July 31, 2022

– Revenue for Second Quarter of Fiscal 2023 Increased 31.5% to $496.5 million – – Record Quarterly EPS of $1.10 for Second Quarter of Fiscal 2023 – – Increases Fiscal 2023 Modeling Assumptions, Expects Fiscal 2023 EPS in Range of $3.70-$4.00 – WEST FARGO, N.D., Aug. 25, 2022 (GLOBE NEWSWIRE) — Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, today reported financial results for the fiscal second quarter ended July 31, 2022. David Meyer, Titan Machinery’s Chairman and Chief Executive Officer, stated, “We are pleased to deliver second quarter earnings per share of $1.10 — which marks the highest quarterly earnings performance in our Company’s history. This is the result of our team’s unrelenting focus on customer...

Continue reading

Bionomics reports Full Year Financial Results

ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective Negative Allosteric Modulator of the 7 nicotinic acetylcholine receptor (“7 receptor”) for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). During the fiscal year ended 30 June 2022, Bionomics made several advancements with the ongoing clinical development of BNC210. After receiving US...

Continue reading

Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine

— SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) — — Favorable tolerability and safety profile in adolescents, consistent with results previously observed in adults — — Clover plans to submit adolescent data to global regulatory authorities, in addition to its ongoing submissions for use in adults and elderly, to broaden potential use of SCB-2019 (CpG 1018/Alum) across age groups and as a universal COVID-19 booster vaccine — SHANGHAI, China, Aug. 25, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced positive data from...

Continue reading

Neurostimulation Devices Market to hit USD 20.1 billion by 2030, says Global Market Insights Inc.

Neurostimulation devices industry is projected to register 11% CAGR between 2022 and 2030 owing to rising acceptance of minimally invasive surgeries across the globe. Selbyville, Delaware, Aug. 25, 2022 (GLOBE NEWSWIRE) — Neurostimulation Devices Market value is set to cross USD 20.1 billion by 2030, according to a new research report by Global Market Insights Inc. Patients with debilitating psychiatric and neurological disorders are benefiting from technological advancements in different types of neurostimulation devices. For example, in May 2019, Nevro launched Omnia, a next-generation spinal cord stimulation system, to treat chronic pain in the U.S. Apart from their increasing adoption for pain management, of neurostimulation devices are deemed effective for use in deep brain stimulation for movement control and other applications. Request...

Continue reading

Gabriel Holding A/S – three quarters of the 2021/22 financial year

Summary: After three quarters Gabriel Holding A/S delivers 39% revenue growth to DKK 812.7 million and operating profit (EBIT) of DKK 60.1 million, an increase of 40%.  Selected financial ratios:Revenue increased by DKK 226 million (39%) to DKK 812.7 million (DKK 586.4 million)Revenue in the third quarter increased by DKK 91.8 million to DKK 289.9 million (DKK 198.1 million), an increase of 46% All business units contributed to the realised growth in the first nine months of the yearThe gross margin was 32.9% (37.9%) Operating profit (EBIT) increased by 40% to DKK 60.1 million (DKK 43.0 million)Operating profit (EBIT) in the third quarter increased by 21% to DKK 16.1 million (DKK 13.3 million)Net finance income and costs in the period was positive by DKK 7.4 million, compared to an expense of DKK 5.5 million in the same period...

Continue reading

With 39.2% CAGR, Global Virtual Reality in Manufacturing Industry Size Worth USD 14.8 Billion in 2026

According to Fortune Business Insights, the global Virtual Reality in Manufacturing Industry Size is projected to reach USD 14.8 billion in 2026, at CAGR of 39.2% during forecast period; Presence of Established IT Infrastructure May Help North America to Continue Dominance Pune, India, Aug. 25, 2022 (GLOBE NEWSWIRE) — A recently published report by Fortune Business Insights titled, “Virtual Reality in Manufacturing Industry Share, Trends & Industry Analysis, By Component, By Application and Regional Forecast, 2022-2026,” states that the market value was USD 924.7 million in 2018 and is expected to rise at a CAGR of 39.2% to reach USD 14,887.0 million by the end of 2026. The global virtual reality in manufacturing industry size is projected to witness substantial growth owing to the increasing trend of digitalization accepted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.